GSK3B and early-onset autosomal dominant Alzheimer disease: In recent years, many Keap1–Nrf2 PPI inhibitors and GSK3β inhibitors have been reported for various indications, such as Alzheimer’s disease, cancers, Parkinson’s disease, kidney diseases, Acetaminophen (APAP)–induced liver injury, and ferroptosis [30,70,71,72,73,74].